Bone Marrow Transplantation News

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

A multimodal phone app proved feasible for addressing sexual dysfunction among hematopoietic stem cell transplant survivors, according to results presented at Tandem Meeting | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

Allogeneic hematopoietic stem cell transplantation after CD19 chimeric antigen receptor T-cell therapy is thought to improve leukemia-free survival.

SAN DIEGO — The volume of hematopoietic stem cell transplantation procedures for advanced diffuse large B-cell lymphoma has declined precipitously since 2019, study results presented at ASH Annual Meeting and Exhibition showed.

The microbiome is linked to myriad processes in human health and disease.

This year’s ASH Annual Meeting featured several high-impact abstracts.

In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.